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Summary
The htrman 'protective protein' (HPP), also known in the literature as protective protein/cathepsin
A (PPCA), forms a multi-enzyme complex with B-D-galactosidase and N-acetyl-cr-neuraminidase
in the lysosomes, protecting these two glycosidases from degradation. In humans, deficiency of FIPp
leads to the lysosomal storage disease galactosialidosis. Major characteristics of this disease include
cardiac and kidney involvement, skeletal dysplasia, angiokeratoma, dysmorphism, progressive
neurological deterioration, reduced life expectancy and in some cases mental retardation. HPP is
synthesized as a 54 kDa precursor containing 452 residues. Endoproteolytic processing of the
precursor form of HPP releases a serine carboxypeptidase activity with an acidic pH optimum and
substrate specificity identical to cathepsin A. This maturation event involves the removal of a 2 kDa
'excision peptide' from within the 54 kDa precursor, yielding a32 and 20 kDa polypeptide chain still
held together with disulfide bridges.
This thesis describes the three-dimensional structure determination of HPP in the precursor form by
X-ray crystallography. Chapter 2 describes the over-expression, purification and crystallization
procedure which finally yielded crystals diffracting to high resolution. A very high degree of protein
purity was crucial to obtain crystals. Six different crystal forms were found, but only one yielded
high resolution diffraction data suitable for the structure determination. These crystals grow in space-
group P22t2 with cell dimensions a= II5.04 À, b = 148.11 À, 
" 
= 80.91À. Due to the radiation
sensitivity of these crystals, cryo-cooling was used during data collection, after a suitable cryo-
protection procedure had been developed. A native data set was collected to 2.0 À thanks to the
intense X-ray beam at Stanford Synchrotron Radiation l,aboratories (SSRL).
The structure, a dimer with 452 residues per subunit, was solved by a combination of molecular
replacement and two-fold averaging, as described in Chapter 3. A very paÍial multi-alanine
monomer search probe was constructed from the atomic coordinates of the wheat serine
carboxypeptidase, which shares 307o sequence identity with HPP. The search probe contained only
30Vo of the scattering mass in the asymmetric unit, yet was successful in finding the positions of the
two monomers thought to be present, based on the expected solvent content of the crystals.
Subsequent "bootstrapping cycles" entailing two-fold averaging and model expansion rounds, easily
retrieved the electron density for residues initially missing from the model. ln particular, it proved
possible to add a domain, more than 110 residues, to the starting model using this procedure. ln total
314 residues per asyrnmetric unit were added to the 588 residues of the initial model. The current
model has an \",o, of 21.3 Vo and an &,"" of 26.8 Vo for data between 8 and 2.2 L.
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The crystal structure of FIPP in the precursor form reveals that the monomer is comprised of a'core'
domain, housing the catalytic triad, and a'cap'domain. The latter consists of a'helical' subdomain
and a' 'maturation' subdomain. Subunit comparison with the distantly related serine
carboxypeptidases from wheat (CPW) and yeast (CP)), reveals that the 'cap' domain of HPP differs
significantly from that of its relatives, in two ways. Firstly, a 49 residue maturation subdomain is
present in the HPP precursor structure, and secondly, the orientation of two out of the three helices
forming the helical subdomain differs by a r of 25 and 90o respectively. In addition, comparison of
the dimers shows that the two monomers in the HPP dimer differ in mutual orientation by a large
15 " rotation, as compared to the CPW dimer.
The crystal structure of HPP in the precursor form, reveals an activation mechanism that appears
to be unique among the protease families, for which the structure of the zymogen is known (Chapter
4). The residues forming the catalytic machinery, i.e. the triad and oxyanion hole, in the structures
of HPP(inactive), CPW (active) and CPY (active) sr:perimpose with a root mean square deviation
of 0.4 À, indicating that the enzymatic machinery in the precursor HPP is correctly poised for
catalysis. But in the precursor the substrate binding sites and catalytic triad are rendered solvent
inaccessible by a polypeptide strand from the maturation subdomain (residues 272 - 277), which
unexpectedly does not coincide with the 2 kDa'excision'peptide (residues 285 - 298). The excision
peptide is also located in the maturation subdomain, but is found at the protein surface, where it is
solvent and protease accessible. Thus mere removal of the excision peptide, can not be sufficient to
open up the active site. The activation of HPP must entail a sequence of events that has not been
previously observed in zymogen activation of the serine proteases (trypsinogen, chymotrypsinogen),
zinc metalloproteases (procarboxypeptidase A and B) and aspartic proteases (pepsinogen). Unlike
other serine protease zymogens, the enzymatic machinery in the HPP precursor apparently does not
need to undergo conformational changes to become catalytically active. In contrast to what is found
in the zymogens of zinc metalloproteases and aspartic proteases, the polypeptide segment in HPP
physically rendering the catalytic triad solvent inaccessible, is not cleaved off to form the active
enzyme ! The activation of HPP must therefore be a multi-step process, involving removal of the 2
kDa excision peptide accompanied by major conformational rearrangement of the rest of maturation
subdomain (up to 35 residues) to open up the active site.
The atomic model of HPP has also provided a structural basis for the combined deficiency of B-D-
galactosidase and N-acetyl-cr-neuraminidase, found in galactosialidosis patients. In Chapter 5, ten
amino acid substitutions found in patients with galactosialidosis were localized in the three-
dimensional structure of HPP, and their impact on protein structure and stability assessed in
modelling studies. None of the mutations are found in the active site or at the protein surface, as
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would be expected for mutations disrupting enzymatic or protective functions respectively. All the
mutations however, appear to diminish the protein stability. The eight Class 1 mutations,
characterized biochemically by the lack of mature protein reaching the lysosome and associated with
a severe phenotype, are thought to have a dramatic effect on the protein integrity. The two Class tr
mutations, characterized by residual protein reaching the lysosomes, and associated with a milder
phenotype, appear to have a much milder effect on the protein stability. The observation that all the
amino acid substitutions appear to affect protein stability but not functional sites, agrees with the
expectation that it is highly unlikely for a single amino acid substitution to disrupt both
the B-D-galactosidase and N-acetyl-cr-neuraminidase binding sites (and enzymatic machinery).
In future, the crystal structure of the precursor HPP, will hopefully continue to provide insight and
new ideas for experiments. A structure-based mutagenesis trategy has been designed to identify
potential binding sites for B-D-galactosidase and N-acetyl-cr-neuraminidase, based on the one hand
on the homology between the human, mouse and chicken protective proteins and on the other, on
the knowledge that they show different capacities to rescue human p-D-galactosidase and N-acetyl-
cr-neuraminidase, upon uptake by cultured galactosialidosis fibroblasts. In addition, the structure may
provide clues as to the tertiary structural element recognized by the mannose-6-phosphate (M-6-P)
phosphotransferase that has been proposed to be common to many lysosomal enzymes, which utilize
the M-6-P dependent routing pathway to the lysosomes.
In the far future, structure determination of B-D-galactosidase and N-acetyl-cr-neuraminidase,
respectively, will allow for more pieces to be added to the exciting multi-enzyme complex puzzle.
kr particular, the localization of the mutations found in G", gangliosidosis patients versus those with
Morquio B will determine the protein structural basis for the two different diseases.
Answers to the central question revolving around how multi-enzyme complex formation alters or
enhances properties of the three enzymes HPP, B-D-galactosidase and N-acetyl-cr-neuraminidase,
will come from determining the structure of the whole multi-enzyme complex, probably by electron
cryo-microscopy techniques. Does complex formation actually render the multi-enzyme complex
substrate specific ? How does complex formation protect the two glycosidases from degradation ?
And why is incorporation of N-acetyl-cr-neuraminidase in the complex apparently necessary for
activation of this enzyme ? The structure determination of the HPP:B-D-galactosidase:N-acetyl-cr-
neuraminidase complex will be a tremendous feat, extending the boundaries of what is currently
technically feasible; it is only with great personal courage that these boundaries on progress will be
pushed aside.
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